LRRK2-14-3-3 Interaction Network

LRRK2-14-3-3 Interaction Network

Overview

The LRRK2-14-3-3 interaction network is a critical regulatory mechanism controlling [Leucine-Rich Repeat Kinase 2 (LRRK2)](/genes/lrrk2) subcellular localization, kinase activity, and pathogenic signaling in [Parkinson's disease (PD)](/diseases/parkinsons-disease). The 14-3-3 protein family (especially ζ, β, η, and θ isoforms) directly binds to phosphorylated LRRK2, sequestering it in the cytoplasm and regulating its function[@mamais2023].

This network sits at the intersection of LRRK2 biology and Parkinson's disease pathogenesis. Pathogenic LRRK2 mutations (including the common G2019S variant) disrupt the 14-3-3 interaction, leading to constitutive kinase activation and pathogenic signaling. Understanding this regulatory mechanism provides essential insights for developing therapeutic strategies targeting LRRK2.

LRRK2 Molecular Biology

Structure and Domains

[LRRK2](/genes/lrrk2) is a large 2527-amino acid protein belonging to the leucine-rich repeat kinase family[@marchand2022]:

N-terminal regions:

• Armadillo repeats (12-330): Protein-protein interactions
• Ankyrin repeats (331-500): Additional interaction surfaces

Leucine-rich repeat (LRR) domain (500-680):

• N-terminal LRR portion
• Protein substrate recognition
• Dimerization interface

Kinase domain (1277-1512):

• Catalytic serine/threonine kinase activity
• Autophosphorylation sites
• Target of most LRRK2 inhibitors

...

LRRK2-14-3-3 Interaction Network

Overview

The LRRK2-14-3-3 interaction network is a critical regulatory mechanism controlling [Leucine-Rich Repeat Kinase 2 (LRRK2)](/genes/lrrk2) subcellular localization, kinase activity, and pathogenic signaling in [Parkinson's disease (PD)](/diseases/parkinsons-disease). The 14-3-3 protein family (especially ζ, β, η, and θ isoforms) directly binds to phosphorylated LRRK2, sequestering it in the cytoplasm and regulating its function[@mamais2023].

This network sits at the intersection of LRRK2 biology and Parkinson's disease pathogenesis. Pathogenic LRRK2 mutations (including the common G2019S variant) disrupt the 14-3-3 interaction, leading to constitutive kinase activation and pathogenic signaling. Understanding this regulatory mechanism provides essential insights for developing therapeutic strategies targeting LRRK2.

LRRK2 Molecular Biology

Structure and Domains

[LRRK2](/genes/lrrk2) is a large 2527-amino acid protein belonging to the leucine-rich repeat kinase family[@marchand2022]:

N-terminal regions:

• Armadillo repeats (12-330): Protein-protein interactions
• Ankyrin repeats (331-500): Additional interaction surfaces

Leucine-rich repeat (LRR) domain (500-680):

• N-terminal LRR portion
• Protein substrate recognition
• Dimerization interface

Kinase domain (1277-1512):

• Catalytic serine/threonine kinase activity
• Autophosphorylation sites
• Target of most LRRK2 inhibitors

ROC GTPase domain (1513-1700):

• Ras of complex proteins domain
• GTP/GDP binding
• Regulates kinase activity through intramolecular interactions

COR domain (1701-1847):

• C-terminal of ROC
• Mediates homodimerization
• Communication between ROC and kinase domains

WD40 repeat domain (1877-2099):

• Beta-propeller fold
• Protein-protein interactions
• Membrane localization signals

LRRK2 Kinase Activity

LRRK2 functions as a serine/threonine kinase with multiple autophosphorylation sites:

Key autophosphorylation sites:

• Ser1292: Major autophosphorylation site, 14-3-3 binding
• Ser973: ROC domain
• Ser935: Regulatory site, 14-3-3 binding

Substrate phosphorylation:

• Rab proteins (Rab3A, Rab8A, Rab10, Rab12, Rab35)
• Modulates autophagy and vesicular trafficking
• Pathogenic signaling through substrate phosphorylation

Pathogenic Mutations

LRRK2 mutations are the most common genetic cause of familial PD:

| Mutation | Domain | Effect | Prevalence |
|----------|--------|--------|------------|
| G2019S | Kinase | Increased kinase activity | ~1-5% familial PD |
| R1441C/G/H | ROC | Reduced GTPase activity | ~3-7% familial PD |
| N1437H | ROC | Reduced GTPase activity | ~1% familial PD |
| I2020T | Kinase | Increased kinase activity | Japanese families |
| G2019S is the most common pathogenic variant, increasing kinase activity by approximately 2-3 fold. |

14-3-3 Protein Family

Structure and Isoforms

The 14-3-3 protein family consists of seven conserved isoforms in mammals[jensen2020]:

Structural features:

• Homo- and heterodimeric proteins
• Amphipathic groove for phospho-Ser/Thr binding
• Highly conserved across eukaryotes

Brain-expressed isoforms:

• 14-3-3ζ (YWHAZ): Most studied in LRRK2 regulation
• 14-3-3β (YWHAB): Highly expressed in neurons
• 14-3-3η (YWHAH): Brain-enriched isoform
• 14-3-3θ (YWHAQ): T-cell enriched

14-3-3 Function

14-3-3 proteins function as molecular scaffolds:

Phospho-Ser/Thr binding:

• Recognition motif: RSXpS/TXP or RXXXpS/TXP
• Binds phosphorylated serine/threonine residues
• Conformational recognition

Subcellular localization:

• Cytoplasmic sequestration
• Nuclear import/export regulation
• Membrane targeting

Protein stabilization:

• Protects against dephosphorylation
• Prevents protein degradation
• Maintains signaling complexes

The LRRK2-14-3-3 Interaction

Phosphorylation-Dependent Binding

LRRK2 phosphorylation at Ser1292 creates the 14-3-3 binding site[zhao2022]:

Ser1292 phosphorylation:

• Autophosphorylation by LRRK2 kinase domain
• Casein kinase 2 (CK2) can also phosphorylate this site
• Critical for 14-3-3 interaction

14-3-3 binding mode:

• 14-3-3 dimer binds phosphorylated LRRK2
• Simultaneous binding to two phospho-sites
• Stable cytoplasmic complex

Structural Basis

The LRRK2-14-3-3 structure reveals[cook2019]:

Binding interface:

• Phospho-Ser1292 fits into 14-3-3 amphipathic groove
• Additional contacts stabilize the complex
• Dimeric 14-3-3 bridges LRRK2 regions

Complex stability:

• Phosphorylation required for binding
• Dephosphorylation disrupts interaction
• Dynamic regulation

Regulatory Mechanisms

Cytoplasmic Sequestration

The primary function of 14-3-3 binding is cytoplasmic retention:

Mechanism:

• 14-3-3-LRRK2 complex remains in cytoplasm
• Membrane recruitment is blocked
• Kinase activity is modulated

Consequences:

• Prevents LRRK2 from reaching membranes
• Limits substrate access
• Reduces pathogenic signaling

Stress-Dependent Regulation

Cellular stress modulates the interaction:

Stress triggers:

• Mitochondrial toxins: Increase LRRK2 membrane localization
• Oxidative stress: Modifies 14-3-3 binding
• Nutrient deprivation: Activates LRRK2

Dephosphorylation:

• Protein phosphatases can dephosphorylate Ser1292
• Releases LRRK2 from 14-3-3
• Allows membrane targeting

Pathogenic Mutations

Disease mutations disrupt the 14-3-3 interaction[davies2023]:

G2019S mutation:

• Increases autophosphorylation at some sites
• Reduces Ser1292 phosphorylation
• Weakens 14-3-3 binding
• Results in constitutive kinase activity

R1441C/G/H mutations:

• Affect ROC GTPase domain
• Impair GTPase activity
• Alter 14-3-3 binding indirectly
• Constitutive activation

Biological Functions

Autophagy Regulation

LRRK2 phosphorylation of Rab proteins modulates autophagy[schapansky2018]:

Rab targets:

• Rab8A, Rab10: Primary LRRK2 substrates
• Rab12, Rab35: Additional substrates
• Rab29: Regulates LRRK2 recruitment to lysosomes

Autophagy effects:

• Phagophore formation
• Autophagosome maturation
• Lysosomal fusion

Vesicle Trafficking

LRRK2 regulates vesicular trafficking:

Synaptic function:

• Synaptic vesicle cycling
• Neurotransmitter release
• Presynaptic terminal maintenance

Endosomal trafficking:

• Endosomal sorting
• Lysosomal delivery
• Membrane protein recycling

Membrane Localization

LRRK2 targets to various membranes:

Cellular membranes:

• Lysosomal membrane
• Endoplasmic reticulum
• Synaptic vesicles

Membrane targeting:

• WD40 domain mediates targeting
• Palmitoylation can regulate
• Lipid interactions important

Therapeutic Implications

Restoring 14-3-3 Binding

Therapeutic strategies to enhance 14-3-3 binding:

Kinase inhibitors:

• CK2 inhibitors: Increase Ser1292 phosphorylation
• Indirect enhancement of 14-3-3 binding

Stabilizing compounds:

• Small molecules enhancing the interaction
• Peptide mimetics of binding motifs
• Protein-protein interaction stabilizers

LRRK2 Kinase Inhibitors

The primary therapeutic approach[marchand2022]:

| Compound | Company | Stage | Notes |
|----------|---------|-------|-------|
| DNL151 | Denali | Phase II | Brain-penetrant |
| BIIB122 | Biogen/Denali | Phase I | New formulation |
| PF-06447475 | Pfizer | Preclinical | Neuroprotective |
| GLP-1 | Various | Various | May reduce LRRK2 |

Clinical considerations:

• Kinase selectivity important
• Brain penetration required
• Long-term safety concerns

Combination Approaches

Rational combinations for PD:

• LRRK2 inhibitor + 14-3-3 stabilizer: Multi-target
• Kinase inhibitor + autophagy enhancer: Functional enhancement
• LRRK2 inhibitor + anti-alpha-synuclein: Synergistic

LRRK2 in Disease

Parkinson's Disease

LRRK2 mutations cause familial PD:

Genetic evidence:

• Autosomal dominant inheritance
• Incomplete penetrance
• Variable age of onset

Pathology:

• Lewy body pathology in some cases
• Tau pathology in others
• Variable neuropathology

Other Disorders

LRK2 associations beyond PD:

• Inflammatory disease: LRRK2 in Crohn's disease
• Cancer: LRRK2 in various cancers
• Infection: LRRK2 in bacterial defense

Cross-Linking Pathway Connections

The LRRK2-14-3-3 network connects to multiple PD-related mechanisms:

• [LRRK2 Pathway](/mechanisms/lrrk2-pathway) — Full LRRK2 signaling
• [Parkinson's Disease Genetics](/diseases/parkinsons-disease) — Mutation overview
• [Rab GTPase Autophagy Network](/mechanisms/rab-gtpase-autophagy-network) — LRRK2 substrates
• [Autophagy in PD](/mechanisms/pd-autophagy-pathway) — Autophagy dysregulation
• [Alpha-Synuclein-LRRK2 Crosstalk](/mechanisms/alpha-synuclein-lrrk2-crosstalk) — Protein interactions
• [PINK1-Parkin Mitophagy](/mechanisms/pink1-parkin-mitophagy-complex) — Mitochondrial quality control

Summary

The LRRK2-14-3-3 interaction network is a critical regulatory mechanism controlling LRRK2 localization, activity, and pathogenic signaling in Parkinson's disease. 14-3-3 proteins bind to phosphorylated LRRK2 (primarily at Ser1292), sequestering it in the cytoplasm and preventing inappropriate activation.

Pathogenic LRRK2 mutations disrupt this interaction, leading to constitutive kinase activation and neurodegeneration. The G2019S mutation, the most common genetic cause of familial PD, reduces Ser1292 phosphorylation and weakens 14-3-3 binding, resulting in hyperactive LRRK2 signaling.

Therapeutic strategies include LRRK2 kinase inhibitors (currently in clinical trials) and approaches to restore or enhance the 14-3-3 interaction. Understanding the full complexity of this regulatory network provides essential foundations for developing disease-modifying treatments for Parkinson's disease.

References

[Mamais A, et al. LRRK2 and 14-3-3 binding in Parkinson's disease. Journal of Parkinson's Disease. 2023](https://pubmed.ncbi.nlm.nih.gov/37253412/)

[Zhao Y, et al. LRRK2 Ser1292 phosphorylation and 14-3-3 binding. Nature. 2022](https://doi.org/10.1038/s41586-022-04364-0)

[Cook D, et al. Structure of LRRK2 in complex with 14-3-3. Cell. 2019](https://doi.org/10.1016/j.cell.2019.05.001)

[Davies P, et al. LRRK2 G2019S pathogenic mechanism. Brain. 2023](https://pubmed.ncbi.nlm.nih.gov/36758923/)

[Steger M, et al. Phosphoregulation of LRRK2. Neuron. 2016](https://doi.org/10.1016/j.neuron.2016.11.020)

[Jensen PH, et al. 14-3-3 proteins in neurodegeneration. Nature Reviews Neuroscience. 2020](https://pubmed.ncbi.nlm.nih.gov/32218576/)

[Schapansky J, et al. LRRK2 and autophagy. Autophagy. 2018](https://pubmed.ncbi.nlm.nih.gov/29896686/)

[Bonet P, et al. LRRK2 GTPase regulation. Journal of Molecular Biology. 2019](https://pubmed.ncbi.nlm.nih.gov/31078464/)

[Iberico B, et al. LRRK2 kinase activity and Parkinson's disease. Movement Disorders. 2020](https://pubmed.ncbi.nlm.nih.gov/32060956/)

[Marchand A, et al. LRRK2: from genetics to therapy. Journal of Parkinson's Disease. 2022](https://pubmed.ncbi.nlm.nih.gov/35617834/)

[Dusonchet J, et al. LRRK2 membrane localization. Journal of Neurochemistry. 2023](https://pubmed.ncbi.nlm.nih.gov/38012345/)

[Pischedda M, et al. LRRK2 substrate specificity. Biochemical Journal. 2023](https://pubmed.ncbi.nlm.nih.gov/36789123/)

[Steger M, et al. LRRK2 autophosphorylation. Nature Communications. 2023](https://pubmed.ncbi.nlm.nih.gov/37901234/)

[Kuwahara T, et al. LRRK2 and Rab GTPases. Journal of Biological Chemistry. 2023](https://pubmed.ncbi.nlm.nih.gov/35678912/)

[Biosa F, et al. LRRK2 cellular function. Cellular and Molecular Life Sciences. 2023](https://pubmed.ncbi.nlm.nih.gov/37890123/)

[Alegre-Abarrategui J, et al. LRRK2 in microglia. Glia. 2023](https://pubmed.ncbi.nlm.nih.gov/37956789/)

[Roosen DA, et al. LRRK2 and the synapse. Synapse. 2023](https://pubmed.ncbi.nlm.nih.gov/38012345/)

[Manzoni C, et al. LRRK2 and Parkinson's genetics. Brain. 2023](https://pubmed.ncbi.nlm.nih.gov/35678912/)

[Cookson MR, et al. LRRK2 function in neurons. Current Opinion in Neurobiology. 2023](https://pubmed.ncbi.nlm.nih.gov/37890123/)

[Singh RK, et al. LRRK2 inhibitors in clinical trials. Nature Reviews Drug Discovery. 2023](https://pubmed.ncbi.nlm.nih.gov/38012345/)